TONIX PHARMACEUTICALS HOLDINTNXP
ASignal's systematic analysis rates TNXP as Bearish.
Reflects the latest available analysis · analyzed Oct 15, 2026
The case on TNXP
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (577.9% YoY)
- High gross margin (83.83%)
- Exceptional financial health score (0.9)
- Low debt-to-equity ratio (0.01x)
- High cash position ($176.23M total cash)
- Current ratio of 6.61x indicates strong liquidity
- Negative MACD histogram and declining momentum
- Price trading significantly below SMA20 and SMA50
- Negative operating margin (-314.05%)
- Negative ROE (-81.82%) and ROA (-46.84%)
- Negative enterprise value (-$65.19M) suggests balance sheet concerns
- No news coverage or Reddit mentions — low market sentiment data
See the full verdict on TNXP
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes TNXP
Most investors never get a second opinion, let alone several. ASignal runs TNXP past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.